Vol. 1 No. 5 (2026), Articles
Vol. 1 No. 5 (2026)

CYTOKINE-GUIDED IMMUNOLOGICAL CORRECTION AFTER TOTAL KNEE ARTHROPLASTY IN RHEUMATOID ARTHRITIS: FIRST REAL-WORLD MULTICENTER STUDY FROM UZBEKISTAN

Articles
Published 2026-05-13
Maruf Anorboev
MD, MSc, PhD researcher – Tashkent state medical university, Department of traumatology, orthopedics and neurosurgery
Khalmurad Akhmedov
DSc, Professor- Tashkent state medical university, Department of internal diseases at family medicine No2
Ilkhom Khujanazarov
DSc- Tashkent state medical university, Department of traumatology, orthopedics and neurosurgery No2, Tashkent, Uzbekistan
PDF

How to Cite

Anorboev , M., Akhmedov, K., & Khujanazarov , I. (2026). CYTOKINE-GUIDED IMMUNOLOGICAL CORRECTION AFTER TOTAL KNEE ARTHROPLASTY IN RHEUMATOID ARTHRITIS: FIRST REAL-WORLD MULTICENTER STUDY FROM UZBEKISTAN. INTERNATIONAL CONFERENCE ON MODERN RESEARCH AND SCIENTIFIC INNOVATION, 1(5), 81-84. https://doi.org/10.5281/zenodo.20161914
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver AMA

Download Citation

Endnote/Zotero/Mendeley (RIS) BibTeX

Abstract

This multicenter real-world study from Uzbekistan evaluated cytokine-guided postoperative immunological correction in patients with rheumatoid arthritis undergoing total knee arthroplasty. A total of 106 patients were stratified according to dominant cytokine profiles, including TNF-α, IL-6, and IL-1β, and received pathway-matched biologic therapy with csDMARDs. Over 52 weeks, significant improvements were observed in DAS28, HAQ-DI, VAS pain, CRP, ESR, and cytokine levels. Nearly half of the patients achieved remission, and most reached low disease activity. No prosthetic joint infections, implant failures, or deaths were recorded. These findings suggest that cytokine-guided personalized therapy may improve postoperative recovery, disease control, and safety in rheumatoid arthritis patients after total knee arthroplasty.Начало формы

PDF

References

1. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023–2038. doi:10.1016/S0140-6736(16)30173-8.

2. Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an ACR/EULAR collaborative initiative. Ann Rheum Dis. 2010;69(9):1580–1588. doi:10.1136/ard.2010.138461.

3. Smolen JS, Landewé RBM, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological DMARDs: 2022 update. Ann Rheum Dis. 2023;82(1):3–18. doi:10.1136/ard-2022-223356.

4. Goodman SM, Springer BD, Chen AF, et al. 2022 ACR/AAHKS guideline for the perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty. Arthritis Care Res. 2022;74(9):1399–1408. doi:10.1002/acr.24893.

5. Goodman SM, Springer BD, Chen AF, et al. 2022 ACR/AAHKS guideline for perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip or knee arthroplasty. J Arthroplasty. 2022;37(9):1676–1683. doi:10.1016/j.arth.2022.05.001.

6. Smolen JS, Breedveld FC, Burmester GR, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016;75(1):3–15.

7. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365(23):2205–2219.

8. Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in rheumatoid arthritis. Ann Rheum Dis. 2008;67(11):1516–1523.

9. Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti–tumor necrosis factor monoclonal antibody, for the treatment of rheumatoid arthritis. Arthritis Rheum. 2003;48(1):35–45.

10. Bresnihan B, Alvaro-Gracia JM, Cobby M, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum. 1998;41(12):2196–2204.